ARAC™ – systemic nano-immunotherapy for tumors inaccessible for local treatment or injection

(Antigen Release Agent and Checkpoint inhibitor)

Nanoparticle co-delivering a kinase inhibitor and immunotherapy to kill cancer cells and unleash the power of the immune system

ARAC™ reduces the effective dose of drugs by 5-fold in a metastatic lung tumor model and the effect is immune (CD8) mediated.

Adjuvant loaded ARAC™ leads to cure of lung cancer in mice. 

ARAC™ kills cancer and renders PDL1 low tumors responsive to immunotherapy

Publication:

Reda, M., Ngamcherdtrakul, W., Nelson, M.A., Siriwon, N., Wang, R., Zaidan, H.Y., Bejan, D.S., Reda, S., Hoang, N.H., Crumrine, N.A., Rehwaldt, J.C., Bindal, A., Mills, G.B., Gray, J.W., Yantasee, W. Development of novel immunotherapy based on nanoparticle co-delivering PLK1 and PD-L1 inhibitors for lung cancer treatment. 2021, PREPRINT | View Online